Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide spectrum of clinical symptoms ranging from general fatigue to serious renal and CNS manifestations. Most of the drugs used to treat SLE are old, generically available, and prescribed off-label. To date, Benlysta is the only drug approved for moderate to severe SLE (excluding severe active renal and severe active CNS). The high unmet need in this indication suggests significant commercial opportunity for novel therapies offering a better profile than that of Benlysta.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in December 2017
Key companies: Bristol-Myers Squibb, GlaxoSmithKline, Roche
Key drugs: Azathioprine, Benlysta (belimumab), CellCept (mycophenolate mofetil), cyclophosphamide, hydroxychloroquine, methotrexate, Rituxan/MabThera (rituximab)